|Dr. Travis C. Mickle||Co-Founder, Chairman, Pres & CEO||530.76k||N/A||1973|
|Dr. Sven Guenther||Exec. VP of R&D||364.77k||N/A||1972|
|Ms. Christal M. M. Mickle||Co-Founder and VP of Operations & Product Devel.||N/A||N/A||1979|
|Mr. R. LaDuane Clifton CPA||CFO, Sec. & Treasurer||N/A||N/A||1972|
|Mr. Timothy J. Sangiovanni||VP & Corp. Controller||N/A||N/A||1984|
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.
KemPharm, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.